17:12 EDT Enlivex Therapeutics (ENLV) files $300M mixed securities shelf
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENLV:
- Enlivex’s Promising Clinical Progress and Strategic Collaborations Justify Buy Rating
- Enlivex to Present Allocetra™ Insights at OARSI 2025
- Enlivex Completes Phase II Enrollment for Osteoarthritis Trial
- Enlivex completed enrollment of patients in Phase II trial of Allocetra
- Enlivex Begins Phase I Trial for TMJ Osteoarthritis Treatment